XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds

75,411 resources

By Version

R2: 0
R2B: 0
R3: 3,448
R4: 55,341
R4B: 3,134
R5: 13,264
R6: 224

By Authority

none: 25,640
hl7: 42,405
ihe: 1,382
national: 3,470
who: 2,514

By Realm

none: 22,398
au: 648
be: 387
br: 299
ca: 764
ch: 1,527
cl: 469
cr: 45
cz: 384
de: 2,066
dk: 1,474
ee: 276
eu: 1,253
fi: 87
fr: 1,545
il: 308
in: 163
it: 181
jp: 293
kr: 5
nl: 2,153
no: 26
nz: 79
pl: 83
se: 29
sl: 2
stt: 116
tw: 901
uk: 97
us: 19,481
uv: 17,592
vn: 107
other: 7

Start Prev Rows 47400 - 47600 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.16	Intraarterial Thrombolytic tPA Therapy	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.163	Systolic Blood Pressure	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.171	Abnormal Presentation	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.173	Delivery of Singleton	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.21	Intravenous or Intraarterial Thrombolytic tPA Therapy	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.26	Estimated Gestational Age at Delivery	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.27	Cornual Ectopic Pregnancy	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.38	General Or Neuraxial Anesthesia	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.39	Low Dose Unfractionated Heparin for VTE Prophylaxis	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.41	Glycoprotein IIb IIIa Inhibitors	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.55	Oxytocin	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.56	Dinoprostone	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.58	Delivery Procedures	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.59	Delivery Procedures	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.67	PCI	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.68	Endotracheal Intubation	active	2018-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.69	Endotracheal Intubation	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.98	Delivery of Singleton	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1045.99	Delivery of Singleton	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.225	Opioid Medication Assisted Treatment (MAT) SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.241	Schedule II, III and IV Opioid Medications	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.242	Opioid Use Disorder	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.243	Opioid Use Disorder	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.265	Inpatient, Emergency, and Observation Locations	active	2022-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.269	Medications for Opioid Use Disorder (MOUD)	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.274	NHSN Inpatient Encounter Class Codes	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.277	Emergency Department Location	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.278	Emergency Department Treatment Location	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.283	Emergency Department Location	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.284	Emergency Department Location	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.285	Mental Health Diagnosis without Substance Use Disorders	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.286	Decision to Transfer	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1046.35	Healthcare Agent or Proxy Choices	active	2022-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.10	Breastfeeding	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.100	Familial Hypercholesterolemia	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.102	Rhabdomyolysis	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.107	Low Intensity Statin Therapy	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.12	Liver Disease	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.13	Rhabdomyolysis	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.19	Atherosclerosis and Peripheral Arterial Disease	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.20	Atherosclerosis and Peripheral Arterial Disease	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.21	Atherosclerosis and Peripheral Arterial Disease	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.22	Liver Disease ICD9	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.37	Stable and Unstable Angina	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.39	Cerebrovascular Disease Stroke or TIA	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.41	Ischemic Heart Disease or Related Diagnoses	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.42	Liver Disease	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.43	Liver Disease	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.44	Cerebrovascular Disease Stroke or TIA	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.46	Ischemic Heart Disease or Related Diagnoses	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.47	Stable and Unstable Angina	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.501	Overweight or Obese	active	2025-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.502	Overweight or Obese	active	2018-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.512	Elevated Blood Pressure Reading	active	2019-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.513	Elevated Blood Pressure Reading	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.514	Finding of Elevated Blood Pressure or Hypertension	active	2019-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.515	Bariatric Procedures	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.517	Age related macular degeneration intermediate dry	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.518	Ophthalmologist visit	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.519	Posterior vitreous detachment (PVD)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.521	Ophthalmoscopic exam	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.523	Opthalmoscopic exams with Scleral Depression	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.525	Referral (ophthalmology)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.526	Retina Ultrasound	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.527	Retina visualization inadequate	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.528	Refusal or Noncompliance with treatment	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.529	Vitreous hemorrhage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.530	Vitreous hemorrhage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.536	Macula examination	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.539	Fluorescein angiography	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.541	Optical coherence tomography (OCT)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.542	Intravitreal injection	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.543	Bevacizumab injection	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.544	Ranibizumab injection	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.545	Aflibercept injection	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.552	Uveitis	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.553	Uveitis	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.554	Post Cataract Surgery Cystoid Macular Edema AND Idiopathic Macular Edema	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.555	Macular edema	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.556	Corticosteroids for Injection	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.557	Corticosteroids for Injection	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.560	Tonometry	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.561	Intraocular pressure	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.571	Retinal Vein Occlusion Related Macular Edema	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.576	Vitreous hemorrhage	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.580	Intravitreal and Periocular Injections	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.581	Intravitreal and Periocular Injections	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.582	Corticosteroids for Injection	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.583	Endophthalmitis in the Right Eye	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.584	Endophthalmitis in the Left Eye	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.585	Panophthalmitis in the Right Eye	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.586	Panophthalmitis in the Left Eye	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.587	Lost to follow up	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.588	Uveitis	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.610	Scleral depressed exam	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.611	3 Mirror Goldmann exam	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.612	Scleral depressed exam	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.615	Physical Disability	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.616	Financial difficulty	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.617	Vitreous exam findings	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.619	Scleral depressed exam	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.629	Post operative follow up	active	2020-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.67	Breastfeeding	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.69	Stable and Unstable Angina	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.70	Ischemic Heart Disease or Related Diagnoses	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.71	Cerebrovascular Disease Stroke or TIA	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.73	Breastfeeding	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.85	Familial Hypercholesterolemia	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.89	Rhabdomyolysis	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.9	Outpatient Encounters for Preventive Care	active	2019-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.91	Familial Hypercholesterolemia	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.93	Hypercholesterolemia ICD 9	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.97	High Intensity Statin Therapy	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1047.98	Moderate Intensity Statin Therapy	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1056.50	HIV Lab Tests	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1056.51	Indicators of Human Immunodeficiency Virus (HIV)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1056.52	Indicators of Human Immunodeficiency Virus (HIV)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1056.53	Indicators of Human Immunodeficiency Virus (HIV)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1056.71	Human Immunodeficiency Virus (HIV) Viral Load	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.10	ARBs (Angiotensin Receptor Blockers)	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1000	OIA_V2_GLP1s_RxNorms	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1001	OIA_V2_PCSK9s_RxNorms	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1002	OIA_RFs_Secondary_Prevention_ICD10	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1003	OIA_RFs_Secondary_Prevention_SNOMED	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1004	OIA_RFs_Secondary_Prevention_CPT	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1005	OIA_RFs_Secondary_Prevention_ICD_SM_CPT	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1006	OIA_Asthma_COPD_Combo_Meds	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1007	OIA_Asthma_COPD_Combo_Meds_SABA_SAMA	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1008	OIA_Asthma_COPD_Combo_Meds_LABA_LAMA_ICS	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1009	PAE_Patient_Conditions	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1012	PAE Conditions Short	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1016	OIA_TEST_VS	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1017	Triptan Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1018	NSAID Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1019	Statin Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1021	Penicillin Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1022	Macrolide Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1023	Quinolone Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1025	Beta blocker Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1026	ACE inhibitor Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1027	ARB Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1028	Sulfonylurea Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1030	DPP4i Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1031	GLP1RA Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1032	Beta blocker allergy intolerance	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1033	SGLT2i Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1034	MRA Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1036	Meglitinide Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1037	Alpha glucosidase inhibitor Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1038	TZD Allergy NDFRT	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1041	Hemoglobin	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1042	Hematocrit	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1043	Anemia for Erythropoesis Simulating Agents I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1044	Anemia for Erythropoesis Simulating Agents SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1045	Anemia for Erythropoesis Simulating Agents	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1046	AZT Meds	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1047	Ferritin	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1048	Knee pain I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1049	Knee pain SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.105	conditions_heartfailure	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1050	Knee pain	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1051	Knee decreased ROM SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1052	Knee effusion I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1054	Knee effusion	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1055	Knee crepitus SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1056	OIA_Antiemetics	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1057	OIA_PDE5is	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1058	OIA_Vitamins	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1059	OIA_Plavix	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1061	OIA_Oral_Contraceptives	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1063	OIA_Topical_Steroids	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1064	OIA_Cough_Cold_Meds	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1065	Antiperspirant aluminum salts	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1066	Antiperspirant anticholinergics	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1067	Antieplieptic medications	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1068	Antidepressant medications	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1069	Urinary incontinence SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1070	Urinary incontinence I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1071	Urinary incontinence	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1073	Hemifacial spasm SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1074	Hemifacial spasm I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1075	Hemifacial spasm	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1076	Spasmodic dysphonia SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1077	Physical therapy procedure SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1078	Occupational therapy SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1079	Hyperhidrosis SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1080	Hyperhidrosis I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1081	Hyperhidrosis	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1082	Tic disorder I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1083	Tic disorder SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1084	Tic disorder	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1085	Esophageal achalasia SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1086	Esophageal achalasia I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1087	Esophageal achalasia	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1088	ET propanolol or primidone	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1089	ET topiramate alprazolam or gabapentin	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.109	CKD stage4above I10	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1090	Blephraospasm SCT	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1091	Blepharospasm I10	active	2025-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1078.1092	Blepharospasm	active	2025-05	us	hl7